Beijing Mabworks Biotech Co., Ltd. announced a private placement of 2,095,558 common shares at a price of CNY 71.58 for gross proceeds of CNY 150,000,041.64 on August 1, 2023. The transaction will include participation from new investor, received CNY Betta Pharmaceuticals Co., Ltd. for 2.91% stake. The transaction has been approved by the 6th session of the company?s 4th directorate and the 4th session of the company?s 4th supervisory board.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
36.91 CNY | -0.73% | -1.63% | -28.40% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.40% | 2.13B | |
+19.29% | 80.29B | |
+15.04% | 9.2B | |
-18.33% | 4.67B | |
+43.39% | 4.49B | |
+13.95% | 4.27B | |
+10.87% | 2.25B | |
+15.93% | 2.1B | |
-43.17% | 1.78B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- 300558 Stock
- News Betta Pharmaceuticals Co., Ltd.
- Beijing Mabworks Biotech Co., Ltd. announced that it expects to receive CNY 150.000042 million in funding from Betta Pharmaceuticals Co., Ltd.